drugset / Trial / NCT01033825

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825

Phase 3 Completed 310 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.

Timeline

Start
2010-01
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciclesonide Other / unclassified 160 ug Intranasal
Subject Ciclesonide Other / unclassified 200 ug Intranasal
Subject Ciclesonide Other / unclassified 320 ug Intranasal
Comparator Dexamethasone Small molecule 6 mg Oral